Hemrajani Rekha 4

What Happened Rekha Hemrajani, a director of MaxCyte, was granted a total of 80,000 restricted stock units (RSUs) on June 17, 2026. The Form 4 shows two award entries: 30,421 RSUs and 49,579 RSUs, each reported at $0.00 (no cash paid). These RSUs are contingent rights to receive one share of MaxCyte common stock per RSU if vesting conditions are met. This is a compensation award for a non-employee director, not an open-market buy or sale.

Key Details

• Transaction date: June 17, 2026; filing date: June 22, 2026 (filed 5 days after the grant).
• Awarded: 30,421 RSUs + 49,579 RSUs = 80,000 RSUs; reported acquisition price $0.00.
• Vesting: The award (per footnote) vests on June 17, 2027, subject to continuous service as of the vesting date.
• Nature of award: RSUs (derivative interest) — each RSU represents a contingent right to one share upon vesting.
• Shares owned after transaction: Not specified in the Form 4.
• Timeliness: The Form 4 was filed on June 22 for a June 17 transaction, which is outside the standard two-business-day filing window and appears to be late; late filings can be administrative but are noted by investors.

Context RSUs are common director compensation and convert into actual shares only if and when they vest (here, a one-year time-based vest). Such awards are routine and primarily reflect compensation rather than an immediate market-view signal (unlike open-market purchases). Because these are non-employee director awards under the company’s equity grant policy, they are typically part of regular annual pay for board service.